Lilly/Alkermes'inhaled insulin generates encouraging phase II results
13th Sep 2005, 06:46 GMT
A phase II clinical study evaluating the effect of Eli Lilly and Alkermes' inhaled insulin in patients with type 1 diabetes has produced positive results and a high level of patient satisfaction.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol